BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed PFE catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:22091366b46904a2a93c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261129
DTEND;VALUE=DATE:20261130
SUMMARY:PFE P3 readout (est.): A Study to Learn About the Study Medicine Ca
 lled Rimegepant in Women When Used for Intermittent Prevention of Menstrua
 l Migraine
DESCRIPTION:A Study to Learn About the Study Medicine Called Rimegepant in 
 Women When Used for Intermittent Prevention of Menstrual Migraine\nNCT0664
 1466 | PHASE3 | RECRUITING | sponsor: Pfizer\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nTicker PFE (confidence 0
 .9)\nSource: https://clinicaltrials.gov/study/NCT06641466\nScheduling/refe
 rence data from public records\; dates can move. Not investment\, legal or
  medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06641466
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b2d83be16ddf27164c32@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261202
DTEND;VALUE=DATE:20261203
SUMMARY:PFE P3 readout (est.): B7981027
DESCRIPTION:A Study to Learn About Medicine Called Ritlecitinib in Children
  Aged Between 6 to 12 Years With Severe Alopecia Areata\nNCT07029711 | PHA
 SE3 | ACTIVE_NOT_RECRUITING | sponsor: Pfizer\nPrimary completion date (ES
 TIMATED)\; top-line results usually follow later.\nTicker PFE (confidence 
 0.9)\nSource: https://clinicaltrials.gov/study/NCT07029711\nScheduling/ref
 erence data from public records\; dates can move. Not investment\, legal o
 r medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07029711
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9899bab22cbfcc19087a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261204
DTEND;VALUE=DATE:20261205
SUMMARY:PFE P3 readout (est.): A Study to Learn About the Safety\, Tolerabi
 lity\, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Dise
 ase Vaccine
DESCRIPTION:A Study to Learn About the Safety\, Tolerability\, and Immunoge
 nicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine\nNCT075
 00506 | PHASE3 | RECRUITING | sponsor: Pfizer\nPrimary completion date (ES
 TIMATED)\; top-line results usually follow later.\nTicker PFE (confidence 
 0.9)\nSource: https://clinicaltrials.gov/study/NCT07500506\nScheduling/ref
 erence data from public records\; dates can move. Not investment\, legal o
 r medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07500506
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fd3fda57bf19e0a9d02e@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261208
DTEND;VALUE=DATE:20261209
SUMMARY:PFE P2 readout (est.): A 16-Week Study to Learn About the Study Med
 icine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lum
 ps\, Known by the Medical Term\, Hidradenitis Suppurativa\, or HS.
DESCRIPTION:A 16-Week Study to Learn About the Study Medicine Called Ritlec
 itinib in Adults With Long Lasting Painful Red Skin Lumps\, Known by the M
 edical Term\, Hidradenitis Suppurativa\, or HS.\nNCT07228390 | PHASE2 | AC
 TIVE_NOT_RECRUITING | sponsor: Pfizer\nPrimary completion date (ESTIMATED)
 \; top-line results usually follow later.\nTicker PFE (confidence 0.9)\nSo
 urce: https://clinicaltrials.gov/study/NCT07228390\nScheduling/reference d
 ata from public records\; dates can move. Not investment\, legal or medica
 l advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07228390
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:22ad286ed7fcc89f8577@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261225
DTEND;VALUE=DATE:20261226
SUMMARY:PFE P2 readout (est.): A Study to Learn About Ritlecitinib for the 
 Potential Treatment of Chronic Spontaneous Urticaria in Adults.
DESCRIPTION:A Study to Learn About Ritlecitinib for the Potential Treatment
  of Chronic Spontaneous Urticaria in Adults.\nNCT07219615 | PHASE2 | RECRU
 ITING | sponsor: Pfizer\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nTicker PFE (confidence 0.9)\nSource: https://
 clinicaltrials.gov/study/NCT07219615\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07219615
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d5598d1bd574ac0df1e3@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:PFE P3 readout (est.): VERITAC-3
DESCRIPTION:Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole 
 + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer\nNCT05909397 | PHASE
 3 | ACTIVE_NOT_RECRUITING | sponsor: Pfizer\nPrimary completion date (ESTI
 MATED)\; top-line results usually follow later.\nTicker PFE (confidence 0.
 9)\nSource: https://clinicaltrials.gov/study/NCT05909397\nScheduling/refer
 ence data from public records\; dates can move. Not investment\, legal or 
 medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05909397
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0331a4bf8e69c4f3eb5d@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:PFE P2 readout (est.): PF-07104091 as a Single Agent and in Combina
 tion Therapy
DESCRIPTION:PF-07104091 as a Single Agent and in Combination Therapy\nNCT04
 553133 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Pfizer\nPrimary complet
 ion date (ESTIMATED)\; top-line results usually follow later.\nTicker PFE 
 (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT04553133\nSc
 heduling/reference data from public records\; dates can move. Not investme
 nt\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04553133
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f0a4a8fc095e2ca1f302@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:PFE P3 readout (est.): Continued Access Study for Participants Deri
 ving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
DESCRIPTION:Continued Access Study for Participants Deriving Benefit in Pfi
 zer-Sponsored Avelumab Parent Studies That Are Closing\nNCT05059522 | PHAS
 E3 | ACTIVE_NOT_RECRUITING | sponsor: Pfizer\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nTicker PFE (confidence 0
 .9)\nSource: https://clinicaltrials.gov/study/NCT05059522\nScheduling/refe
 rence data from public records\; dates can move. Not investment\, legal or
  medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05059522
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e743e178ded34787a2fc@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270118
DTEND;VALUE=DATE:20270119
SUMMARY:PFE P3 readout (est.): RENOIR
DESCRIPTION:Study to Evaluate the Efficacy\, Immunogenicity\, and Safety of
  RSVpreF in Adults.\nNCT05035212 | PHASE3 | ACTIVE_NOT_RECRUITING | sponso
 r: Pfizer\nPrimary completion date (ESTIMATED)\; top-line results usually 
 follow later.\nTicker PFE (confidence 0.9)\nSource: https://clinicaltrials
 .gov/study/NCT05035212\nScheduling/reference data from public records\; da
 tes can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05035212
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:cbfb9f7e3f7dfe29c744@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:PFE P3 readout (est.): A Phase 3 Study in India to Describe the Saf
 ety and Immunogenicity of RSVpreF
DESCRIPTION:A Phase 3 Study in India to Describe the Safety and Immunogenic
 ity of RSVpreF\nNCT07653100 | PHASE3 | RECRUITING | sponsor: Pfizer\nPrima
 ry completion date (ESTIMATED)\; top-line results usually follow later.\nT
 icker PFE (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT07
 653100\nScheduling/reference data from public records\; dates can move. No
 t investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07653100
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ef114689b9b1673837aa@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261026
DTEND;VALUE=DATE:20261027
SUMMARY:PFE APPROVAL: TALZENNA
DESCRIPTION:Approved 2026-10-26: TALZENNA (NDA217439 SUPPL4)\nConfidence: c
 onfirmed\nTicker PFE (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217439\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=217439
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:6c16a678184c1a0542d8@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261026
DTEND;VALUE=DATE:20261027
SUMMARY:PFE APPROVAL: TALZENNA
DESCRIPTION:Approved 2026-10-26: TALZENNA (NDA211651 SUPPL14)\nConfidence: 
 confirmed\nTicker PFE (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=211651
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:4dbc642f10a567472458@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260624
DTEND;VALUE=DATE:20260625
SUMMARY:PFE APPROVAL: IBRANCE
DESCRIPTION:Approved 2026-06-24: IBRANCE (NDA207103 SUPPL24)\nConfidence: c
 onfirmed\nTicker PFE (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=207103
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:c565fa7a8ac72ec0b1a7@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260624
DTEND;VALUE=DATE:20260625
SUMMARY:PFE APPROVAL: IBRANCE
DESCRIPTION:Approved 2026-06-24: IBRANCE (NDA212436 SUPPL12)\nConfidence: c
 onfirmed\nTicker PFE (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212436\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=212436
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:7a56c94d3cbc34c3fd7b@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260605
DTEND;VALUE=DATE:20260606
SUMMARY:PFE APPROVAL: HYMPAVZI
DESCRIPTION:Approved 2026-06-05: HYMPAVZI (BLA761369 SUPPL3)\nConfidence: c
 onfirmed\nTicker PFE (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761369\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761369
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:bf14c9292b3199548d74@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260306
DTEND;VALUE=DATE:20260307
SUMMARY:PFE APPROVAL: XELJANZ
DESCRIPTION:Approved 2026-03-06: XELJANZ (NDA213082 SUPPL13)\nConfidence: c
 onfirmed\nTicker PFE (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213082\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=213082
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:4c98a90bfe3134ca09d9@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260306
DTEND;VALUE=DATE:20260307
SUMMARY:PFE APPROVAL: XELJANZ XR
DESCRIPTION:Approved 2026-03-06: XELJANZ XR (NDA208246 SUPPL27)\nConfidence
 : confirmed\nTicker PFE (confidence 0.9)\nSource: https://www.accessdata.f
 da.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208246\nSc
 heduling/reference data from public records\; dates can move. Not investme
 nt\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=208246
CATEGORIES:approval,confirmed
END:VEVENT
END:VCALENDAR
